

# Key factors influencing the Japanese pharma market

### Key stats:

 $\odot_{\oslash}$ 

() |||| +3.3%/\$48.81bn

The estimated Japanese pharma market revenue in 2025

Japan's pharmaceutical industry remains one of the largest globally,

holding around 5% of the market share

Medicine sales to reach **\$58.40bn by 2029** experiencing a 5-year CAGR of 4.3%

## Strengths:

- Asia-Pacific's largest pharmaceutical market, offering unparalleled business opportunities.
- High pharmaceutical spending per capita, demonstrating a strong demand for advanced healthcare solutions.
- A well-established intellectual property framework that encourages innovation.
- Thriving patented drugs market driven by innovation and a growing need for specialised treatments.
- World-class pharmaceutical manufacturing hub, boasting state-of-the-art production facilities and a high level of investment in research and development.
- Rapidly evolving clinical research landscape, supported by cutting-edge infrastructure and increased collaboration between industry and academia.
- A rapidly aging population, creating a rising demand for healthcare services, pharmaceuticals, and long-term care solutions.
- A highly developed healthcare infrastructure, backed by strong government economic support.

#### Source:

Fitch Solutions, Japan Pharmaceuticals Report Q4 2024 & Pharmaceuticals - Japan | Statista Market Forecast

# Strengths:

- The underdeveloped generic drug market is poised for growth, fuelled by government incentives, ongoing drug shortages, and the expiration of key patents, presenting significant opportunities for expansion.
- Recent updates to regulations and the acceleration of approval processes for innovative drugs are creating enhanced opportunities for multinational companies to introduce new products and expand their market presence.
- Increasing partnerships between domestic and international manufacturers are expected to accelerate sales growth and strengthen marketing reach across the market.
- An aging population coupled with a growing prevalence of chronic and long-term diseases continues to create sustained demand for innovative healthcare solutions, offering substantial opportunities for product developers.

# Challenges



50

Increasing competition from emerging regional companies is shaping the market dynamics, requiring businesses to adopt innovative strategies to maintain a competitive edge

Ongoing government cost-reduction measures are influencing market pricing structures and driving the need for operational efficiency across the sector



For more **information on the Japanese pharma market** and to learn about opportunities at CPHI Japan please visit:

cphi.com/japan